OpenEvidence Valued at $15 Billion Following $250 Million Funding Round

Key Facts

1Health AI startup OpenEvidence raised $250 million in a new funding round.

2The company, known as the ChatGPT for doctors, was valued at $15 billion in the round.

Amid a surging global race to dominate specialized generative AI applications, OpenEvidence has emerged as a pivotal player in the medical sector. According to reports, the health AI startup, often described as the "ChatGPT for doctors," has successfully raised $250 million in a fresh funding round. This capital injection has propelled the company's valuation to $15 billion, underscoring the significant premium investors are placing on AI tools tailored for healthcare professionals.

This funding milestone highlights the continued concentration of liquidity within AI infrastructure and specialized applications. In the broader economic context, market data shows a mixed backdrop; Germany's Producer Price Index rose 4.6% year-on-year in September 2026, while UK retail sales grew by 2.4% annually. The substantial valuation for OpenEvidence suggests that high-tier health-tech ventures continue to attract capital even as broader consumer and industrial sectors face varying inflationary pressures.

Moving forward, market participants are closely watching how private AI firms sustain these multi-billion dollar valuations. While direct instrument prices remain unavailable for this private entity, upcoming catalysts such as the speech by the Fed's Goolsbee will be monitored for broader sentiment. Furthermore, the trajectory of monetary policy under Fed Chair Kevin Warsh remains a critical factor influencing the flow of venture capital into high-growth technology sectors.